The present was undertaken with the objectives of diagnosing hepatic dysfunction on basis of clinical, hematobiochemical, digital imaging and monitoring the therapeutic response to different regimens. For this, a comprehensive study was undertaken on 18 dogs suffering from hepatic dysfunction. Hepatic dysfunction was found to be predominant in the dogs of senile age group >8years (33.33%), followed by 4- 8 years (27.78%), <1 year (22.22%) and 1-4 year (16.67%). Breed wise occurrence revealed that most hepatic dysfunction cases were in Labrador Retriever (22.22%). Sex wise occurrence revealed that males (61.11%) were predominantly affected than females (38.88%). Clinical manifestations recorded in hepatic dysfunction were lethargy to depression, anorexia, vomition, pale mucosa, diarrhoea, polyuria/polydipsia, pain on abdominal palpation, fever, ascites, icterus, peripheral oedema, emaciation, melena, and petechial haemorrhages. The overall haemato-biochemical changes of dogs with hepatic dysfunction revealed anaemia, neutrophilic leukocytosis, prolonged prothrombin time, hypoproteinemia, hyperbilirubinemia and rise of serum liver enzymes (ALT, AST, ALP and GGT). The acute hepatic dysfunction had significantly higher albumin level than globulins level as compared to the chronic hepatic dysfunction. Hepatic radiography and ultrasonography were very useful in diagnosing hepatic dysfunction; however, with ultrasonography, detailed information pertaining to the liver dysfunction could be obtained. The presence of bilirubinuria and bilirubin crystals in the urine was suggestive of canine hepatic dysfunction. In the therapeutic management of hepatic dysfunction, incorporation of Ursodeoxycholic acid and SAMe with silybin (Lisybin) to therapy enhances clinical improvement in hepatic dysfunction and helps restoring normal haemato-biochemical values. Regular screening of apparently healthy dogs will help in early detection of hepatic dysfunction.